Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: The Biopharmaceutical Contract ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

Speaking with Stat ahead of his exit, Robert Califf expressed concern about the potential for brain drain in government. Other news is on promising drugs for lung cancer patients, the upcoming J.P.

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

Health-care companies rose as a reported U.S. death from bird flu stoked fears of a new pandemic, boosting shares of vaccine makers.

Current health news includes Trump considering protective measures for gas appliances against regulatory changes. The WHO ...

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would ...

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...